MedTrace Logo

Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess

NCT02856763 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2021-01-20

No results posted yet for this study

Summary

To identify predictive factors of adalimumab (anti TNF) response in patients with luminal Crohn's disease complicated by intra-abdominal and/or pelvic abscess after complete resolution of infection.

Conditions

Sponsors & Collaborators

  • Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

    lead OTHER

Principal Investigators

  • Yoram Bouhnik, MD · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

  • Guillaume Pineton de Chambrun, MD · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2020-01-31
Completion
2020-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02856763 on ClinicalTrials.gov